Cryoport, Inc. (NASDAQ:CYRX) Receives $12.29 Consensus Target Price from Analysts

Shares of Cryoport, Inc. (NASDAQ:CYRX) have received a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $12.29.

Several brokerages have recently commented on CYRX. UBS Group boosted their target price on Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a report on Friday, October 18th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of Cryoport in a report on Friday, January 17th. Guggenheim began coverage on Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 target price on the stock. Finally, Roth Mkm reduced their target price on Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, November 8th.

Insiders Place Their Bets

In other Cryoport news, Director Ramkumar Mandalam sold 7,369 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $7.46, for a total transaction of $54,972.74. Following the completion of the sale, the director now owns 59,497 shares in the company, valued at approximately $443,847.62. The trade was a 11.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jerrell Shelton sold 50,000 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $6.78, for a total transaction of $339,000.00. Following the sale, the chief executive officer now owns 712,747 shares of the company’s stock, valued at $4,832,424.66. The trade was a 6.56 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 109,869 shares of company stock valued at $735,673. 10.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Cryoport

Institutional investors and hedge funds have recently made changes to their positions in the business. Avanza Fonder AB bought a new stake in shares of Cryoport during the 4th quarter valued at $64,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Cryoport in the 3rd quarter valued at $82,000. Intech Investment Management LLC bought a new stake in shares of Cryoport in the 3rd quarter valued at $105,000. Hsbc Holdings PLC bought a new stake in shares of Cryoport in the 2nd quarter valued at $92,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Cryoport by 9.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,683 shares of the company’s stock valued at $122,000 after buying an additional 1,534 shares in the last quarter. Institutional investors own 92.90% of the company’s stock.

Cryoport Stock Up 0.8 %

NASDAQ CYRX opened at $8.04 on Wednesday. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The stock’s 50 day moving average is $7.78 and its two-hundred day moving average is $7.96. The company has a market capitalization of $397.42 million, a price-to-earnings ratio of -2.38 and a beta of 1.58. Cryoport has a 1-year low of $5.32 and a 1-year high of $20.10.

Cryoport (NASDAQ:CYRX) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.23. The company had revenue of $56.66 million for the quarter, compared to the consensus estimate of $58.13 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same period in the previous year, the business earned ($0.31) earnings per share. Equities analysts forecast that Cryoport will post -0.99 earnings per share for the current fiscal year.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.